Beta Bionics, Inc. Common Stock (BBNX) Stock Analysis

Beta Bionics, Inc. Common Stock (BBNX) is a publicly traded company in the HEALTHCARE sector. It trades at $12.79, carries a market capitalization of $570.39M. This page summarizes the public market data, fundamentals, and frequently asked questions for BBNX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

Market Sentiment

Beta Bionics, Inc. Common Stock currently has a Bearish sentiment score of -0.24.

About Beta Bionics, Inc. Common Stock

Beta Bionics, Inc. (BBNX) is a pioneering medical device company headquartered in Irvine, California, dedicated to revolutionizing diabetes management through innovative insulin delivery systems. By leveraging advanced technology and a patient-centric approach, Beta Bionics strives to enhance the quality of life for individuals dependent on insulin, addressing critical needs within the diabetes community. With a robust focus on research and development, the company is well-positioned to lead ...

GNG Research Analysis

GNG Research scores Beta Bionics, Inc. Common Stock (BBNX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BBNX.

Frequently Asked Questions

Does BBNX pay dividends?

Beta Bionics, Inc. Common Stock (BBNX) does not currently pay a regular dividend.

What is BBNX's market cap?

Beta Bionics, Inc. Common Stock (BBNX) has a market capitalization of $570.39M with a current stock price of $12.79.